Hepatitis C virus
(HCV) infection is a leading cause of end-stage liver disease that
necessitates liver transplantation. The incidence of virus-induced
cirrhosis and hepatocellular carcinoma continues to increase, making
liver transplantation increasingly common. Infection of the engrafted
liver is universal and accelerates progression to advanced liver
disease, with 20–30% of patients having cirrhosis within 5 years of
transplantation. Treatments of chronic HCV infection have improved
dramatically, albeit with remaining challenges of failure and access,
and therapeutic options to prevent graft infection during liver
transplantation are emerging. Developments in directed use of new
direct-acting antiviral agents (DAAs) to eliminate circu...
No comments:
Post a Comment